• Explore /
  • Poster
  • / FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.

FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.

Abstract Poster

Authors

null

Janet E. Murphy

Massachusetts General Hospital Cancer Center, Boston, MA

Janet E. Murphy , Jennifer Yon-Li Wo , David P. Ryan , Wenqing Jiang , Beow Y. Yeap , Lorraine C. Drapek , Lawrence Scott Blaszkowsky , Eunice Lee Kwak , Jill N. Allen , Jeffrey W. Clark , Jason Edward Faris , Andrew X. Zhu , Lipika Goyal , Harvey J. Mamon , Brian M. Wolpin , Keith D Lillemoe , Thomas F. DeLaney , Carlos Fernandez-del Castillo , Cristina Ferrone , Theodore S. Hong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01591733

Citation

J Clin Oncol 35, 2017 (suppl; abstr 4113)

DOI

10.1200/JCO.2017.35.15_suppl.4113

Abstract #

4113

Poster Bd #

105

Abstract Disclosures

Similar Posters

First Author: Janet E. Murphy

First Author: Janet E. Murphy

First Author: Jon Kroll Bjerregaard

First Author: Janet E. Murphy